Richard Philipson

1.8k total citations · 1 hit paper
11 papers, 785 citations indexed

About

Richard Philipson is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Richard Philipson has authored 11 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Surgery, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Rheumatology. Recurrent topics in Richard Philipson's work include Biomedical Ethics and Regulation (2 papers), Eosinophilic Esophagitis (2 papers) and Pharmacological Effects and Toxicity Studies (2 papers). Richard Philipson is often cited by papers focused on Biomedical Ethics and Regulation (2 papers), Eosinophilic Esophagitis (2 papers) and Pharmacological Effects and Toxicity Studies (2 papers). Richard Philipson collaborates with scholars based in United Kingdom, United States and Spain. Richard Philipson's co-authors include Judith C. Brown, Stephen Mallett, Michael E. Wechsler, Frank Moosig, Praveen Akuthota, Ulrich Specks, Steve Yancey, Carol A. Langford, María C. Cid and Raashid Luqmani and has published in prestigious journals such as New England Journal of Medicine, The Journal of Urology and Annals of Oncology.

In The Last Decade

Richard Philipson

11 papers receiving 764 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

2017 589 citations Michael E. Wechsler, Praveen Akuthota et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Richard Philipson

Since Specialization

Citations

This map shows the geographic impact of Richard Philipson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Philipson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Philipson more than expected).

Fields of papers citing papers by Richard Philipson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Philipson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Philipson. The network helps show where Richard Philipson may publish in the future.

Co-authorship network of co-authors of Richard Philipson

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Philipson. A scholar is included among the top collaborators of Richard Philipson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Philipson. Richard Philipson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial 2024 ·Annals of Oncology ·Jérôme Fayette, Gerald A. Thomas, Amaury Daste, (unknown), (unknown), Antonio Rullan, A Levine, Richard Philipson, (unknown)	4
2	MP54-05 EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL 2022 ·The Journal of Urology ·Anirban P. Mitra, Sharada Mokkapati, Tanner Miest, Vikram M. Narayan, Richard Philipson, Seppo Ylä‐Herttuala, David G. Sawutz, Nigel Parker, David J. McConkey, Colin P. Dinney	1
3	Cell & Gene Therapy Commercial Insight – December 2019 2020 ·Cell and Gene Therapy Insights ·Mark Curtis, Richard Philipson	1
4	Cell & Gene Therapy Commercial Insight – December 2019 2019 ·Cell and Gene Therapy Insights ·Mark Curtis, Richard Philipson	1
5	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis breakdown → 2017 ·New England Journal of Medicine ·Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy D. Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, María C. Cid, Raashid Luqmani, Judith C. Brown, Stephen Mallett, Richard Philipson, Steve Yancey, Jonathan Steinfeld, Peter F. Weller, Gerald J. Gleich	589
6	OP0130 Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase iii randomised, placebo-controlled trial 2017 ·Annals of the Rheumatic Diseases ·(unknown), Praveen Akuthota, David Jayne, Paneez Khoury, Amy D. Klion, C. Langford, (unknown), Frank Moosig, Ulrich Specks, (unknown), Raashid Luqmani, J.K. Brown, (unknown), Richard Philipson, (unknown), Jonathan Steinfeld, PF Weller, G.J. Gleich	1
7	A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective COX-2 Inhibitor, GW406381, in Patients With Postherpetic Neuralgia 2009 ·Journal of Pain ·(unknown), Richard Rauck, Steve Quessy, David Blum, Rachel Hodge, Richard Philipson	16
8	Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. 2008 ·PubMed ·(unknown), Keld Østergaard, Richard Philipson, Rachel Hodge, David Blum, Judith C. Brown, Steve Quessy	15
9	The pharmacokinetic and pharmacodynamic consequences of the co‐administration of lamotrigine and a combined oral contraceptive in healthy female subjects 2005 ·British Journal of Clinical Pharmacology ·Jagdev Sidhu, Sarah A. Job, (unknown), Richard Philipson	117
10	A bi-directional pharmacokinetic interaction study of lamotrigine and the Combined Oral Contraceptive (COC) pill in healthy subjects 2005 ·Journal of Pain ·David Blum, (unknown), (unknown), Sarah A. Job, Richard Philipson	7
11	The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects 1985 ·Clinical Pharmacology & Therapeutics ·Adam F. Cohen, M. J. Hamilton, Richard Philipson, A. W. Peck	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact